Control strategies for synthetic therapeutic peptide APIs Part II: Raw material considerations

BioPharm International

Volumn 27, Issue 4, 2014, Pages 24-29

  Eggen, Ivo ^a   Gregg, Brian ^b   Rode, Harold ^c   Swietlow, Aleksander ^d   Verlander, Michael ^e   Szajek, Anita ^f  

^a Aspen Pharma ^*  (South Africa)

^b Bachem Holding AG   (Switzerland)

^c Rode Biologics Consulting   (Canada)

^d AMGEN INC   (United States)

^e PolyPeptide Group   (India)

^f UNITED STATES PHARMACOPEIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; SYNTHETIC PEPTIDE;

ARTICLE; DRUG IMPURITY; DRUG MANUFACTURE; DRUG MONITORING; DRUG PURITY; DRUG QUALITY; DRUG STRUCTURE; PRION DISEASE; QUALITY CONTROL; QUALITY CONTROL PROCEDURES; SYNTHESIS;

EID: 84902293577     PISSN: 1542166X     EISSN: 19391862     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (0)